Breakthrough Clinical Trial: Nuvalent's Cancer Drug Achieves 89% Response Rate, Fast-Track FDA Review Coming
Nuvalent's cancer drug, zidesamtinib, showed positive pivotal data in the ARROS-1 clinical trial for ROS1-positive NSCLC patients, achieving an 89% response rate in TKI-naïve patients and favorable results in TKI pre-treated individuals. The company plans to initiate a rolling New Drug Application (NDA) submission to the FDA in July 2025, with an agreement for Real-Time Oncology Review participation. This development offers renewed hope for a new, potential best-in-class treatment option for advanced ROS1-positive NSCLC.
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Nuvalent, Inc. announced significant progress on its "OnTarget 2026" operating plan, including the FDA's acceptance of an NDA for zidesamtinib for advanced ROS1-positive NSCLC with a PDUFA target date of September 18, 2026. The company also plans to submit an NDA for neladalkib in ALK-positive NSCLC in the first half of 2026 and expand the zidesamtinib indication in the second half. Nuvalent reported a strong cash position of approximately $1.4 billion, providing an operating runway into 2029, and will present at the 44th Annual J.P. Morgan Healthcare Conference.
This Insider Has Just Sold Shares In Nuvalent
Nuvalent's CEO, President & Director, James Porter, recently sold shares worth US$2.7m at an average price of US$97.26, reducing his total holding by 12%. While this was the largest insider sale in the past year, insiders have not bought any shares during the same period, despite owning a significant 2.5% of the company. This selling activity makes analysis cautious, although high insider ownership generally indicates alignment with shareholder interests.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for approximately $676,157 to cover tax obligations from vesting equity awards. Despite this sale, Miller acquired 17,500 shares and stock options for another 17,500 shares through RSUs, increasing her direct ownership to 59,634 shares. The company, while not yet profitable, showcases a strong financial position with more cash than debt and a high current ratio, alongside recent positive analyst ratings and a significant public offering to fund cancer therapy development.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Nuvalent's Chief Development Officer, Darlene Noci, sold 6,492 shares of Class A Common Stock for over $721,000, executed in multiple transactions across January 5th and 6th, 2026. Despite these sales, Noci acquired 17,500 shares and holds an option for an additional 17,500 shares, bringing her direct ownership to 58,117 shares. This comes amidst other significant company developments, including a $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings from UBS, Jefferies, and Truist Securities.
Nuvalent CSO Pelish sells shares worth $501,752
Nuvalent Inc.'s Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations from vested equity awards. These sales were part of a pre-arranged trading plan, and Pelish also acquired additional shares and options. The company recently completed a $500 million public offering and a $315 million royalty deal, with analysts from UBS, Truist Securities, and Jefferies maintaining positive ratings.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold shares totaling $721,320 on January 5th and 6th, 2026. These sales were executed at varying prices per share in multiple transactions. Following these transactions, Noci acquired 17,500 shares and an option to purchase an additional 17,500 shares at an exercise price of $106.82, bringing her direct ownership to 58,117 shares.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for $676,157 to cover tax obligations. Despite the stock appearing overvalued according to InvestingPro's Fair Value assessment, the company recently acquired 17,500 shares and additional stock options valued at $0. This follows a significant public offering of $500 million and a $315 million royalty interest acquisition by Royalty Pharma, alongside positive analyst ratings for Nuvalent's cancer therapies.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for over $676,000 to cover tax obligations from vesting equity awards. Following these sales, Miller acquired 17,500 shares and stock options for another 17,500 shares through RSUs, which vest over several years. The company currently holds more cash than debt but is not yet profitable, with analysts expecting the next earnings report on March 4, 2026.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent Inc.'s Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $501,752 to cover tax obligations. The sales were executed between January 5th and 6th, 2026, through a pre-arranged trading plan, with prices ranging from $96.06 to $98.52. Following these transactions, Pelish directly owns 65,888 shares of the company, and Nuvalent has also recently completed a significant public offering and royalty deal, alongside positive analyst ratings and a new board appointment.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold 6,492 shares of Class A Common Stock for a total of $721,320 in early January 2026. The sales occurred across multiple transactions with prices ranging from $96.06 to $98.52 per share. Following these transactions, Noci directly owns 58,117 shares, and also acquired 17,500 shares with a value of $0 and an option to purchase an equal number of shares at an exercise price of $106.82.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent Chief Scientific Officer Henry E. Pelish sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations, in accordance with a pre-arranged trading plan. Concurrently, Pelish acquired options and shares, increasing his direct ownership in the company. These transactions come amid positive company developments, including a successful public offering, a significant royalty deal, and favorable analyst ratings.
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ: NUVL), sold 6,492 shares of Class A Common Stock for a total of $721,320 across January 5th and 6th, 2026. Despite these sales, Noci acquired 17,500 shares and an option to purchase another 17,500 shares on January 7th. Nuvalent has also recently closed a $500 million public offering, entered a $315 million royalty deal with Royalty Pharma, and received reiterated "Buy" ratings from UBS and Jefferies.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for over $676,000 to cover tax obligations from vesting equity awards. Concurrently, she acquired 17,500 shares and stock options for an additional 17,500 shares through RSUs, which will vest over several years subject to her continued service. Despite these transactions, Nuvalent is not yet profitable, though it holds more cash than debt and has recently completed a significant public offering and secured a royalty deal, attracting positive analyst coverage.
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 5,560 shares of Class A Common Stock for over $500,000 to cover tax obligations, while also acquiring additional shares and options. This news follows several significant developments for Nuvalent, including a successful public offering, a $315 million royalty deal, positive analyst ratings with increased price targets, and the appointment of Ron Squarer to its Board of Directors, reflecting strong progress in its biopharmaceutical ventures.
Nuvalent (NUVL) chief development officer sells $721k in stock
Nuvalent's Chief Development Officer, Darlene Noci, sold shares worth $721,320 in early January 2026, while also acquiring options for new shares. This comes amidst several significant developments for Nuvalent, including a successful $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings from UBS, Jefferies, and Truist Securities. The company also appointed Ron Squarer to its Board of Directors.
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent's Chief Legal Officer, Deborah Ann Miller, sold 6,902 shares of Class A Common Stock for $676,157 to cover tax obligations. Despite the sale, Miller acquired 17,500 shares through RSUs and stock options, increasing her direct ownership to 59,634 shares. The company, currently trading near its 52-week high, has recently completed a $500 million public offering and received positive analyst ratings for its cancer therapies.
Nuvalent (NUVL) chief development officer sells $721k in stock
Nuvalent's Chief Development Officer, Darlene Noci, sold 6,492 shares of Class A Common Stock for over $721,000 in early January 2026, with prices ranging from $96.06 to $98.52 per share. Following these sales, Noci acquired 17,500 shares and an option for another 17,500 shares, bringing her direct ownership to 58,117 shares. This comes amidst other significant company developments, including a $500 million public offering, a $315 million royalty deal with Royalty Pharma, and positive analyst ratings.
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvalent, Inc. announced that its Chief Executive Officer, James Porter, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PT. A live webcast of the presentation will be available on the company's website. Nuvalent is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Royalty Pharma plc has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million from an undisclosed third party. These next-generation tyrosine kinase inhibitors are in development for ALK and ROS1 mutation-positive non-small cell lung cancer, respectively. Neladalkib recently showed positive pivotal results, and zidesamtinib is currently under FDA review with an action date of September 18, 2026.
Nuvalent (NUVL) Valuation After FDA Breakthrough Designation and Investor Optimism in Lung Cancer Franchise
Nuvalent (NUVL) has gained investor attention following FDA Breakthrough Therapy Designation for its lung cancer drug, Zide, and strong share price performance. Despite current valuations suggesting the stock is overvalued by traditional metrics like Price to Book, analysts see potential for further upside. The company's future value hinges on the success of its oncology pipeline and commercialization efforts, particularly for Zide.
Nuvalent Appoints Ron Squarer to Board of Directors
Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company, has appointed Ron Squarer to its Board of Directors, recognizing his extensive experience in oncology drug development and commercialization. Mr. Squarer's expertise is expected to significantly contribute to Nuvalent's pre-launch preparations for zidesamtinib, targeting ROS1-positive non-small cell lung cancer. This appointment aims to strengthen the company's capabilities as it works towards bringing novel kinase inhibitors to patients.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent, Inc. (NUVL) is seen as a strong buy due to its promising lung cancer treatments, Nela and Zide. Truist Securities initiated coverage with a Buy rating and a $140 price target, highlighting the potential regulatory approval of Zide in early 2026. Additionally, Jefferies raised its price target to $164 after positive ALKove-1 trial results for neladalkib, positioning Nuvalent as a significant player in the ALK-positive lung cancer market.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NUVL) is highlighted as a compelling investment due to its promising lung cancer treatments, Nela and Zide. Both drugs are nearing commercialization, with Zide having secured Breakthrough Therapy Designation and expected regulatory approval soon. Analyst firms like Truist Securities and Jefferies have issued "Buy" ratings and raised price targets, citing strong clinical trial results and significant market potential for NUVL's innovative small-molecule therapies.
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NUVL) is considered a strong buy due to its promising lung cancer treatments, Nela and Zide, which are nearing commercialization. Truist Securities initiated a Buy rating with a $140 price target, and Jefferies raised its price target to $164, both impressed by the drugs' performance and potential market share. The company recently completed a public offering, raising approximately $500 million to further support its biopharmaceutical advancements.
Nuvalent (Nasdaq: NUVL) to Raise $500M in Common Stock Offering, 15% Option
Nuvalent (Nasdaq: NUVL) announced an underwritten public offering of Class A common stock aiming to raise $500 million. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares from selling stockholders, from which Nuvalent will not receive proceeds. J.P. Morgan, Jefferies, TD Cowen, and Cantor are serving as joint book-running managers, and the offering is made under an effective shelf registration statement.
Nuvalent (Nasdaq: NUVL) prices $500M public stock offering at $101 per share
Nuvalent, Inc. (Nasdaq: NUVL) announced the pricing of an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, aiming to raise approximately $500.0 million in gross proceeds. The offering is expected to close on November 20, 2025. Additionally, selling stockholders have granted underwriters a 30-day option to purchase up to 742,574 additional shares, though Nuvalent will not receive proceeds from these sales.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders. This offering, managed by J.P. Morgan, Jefferies, TD Cowen, and Cantor, was made pursuant to an automatically effective shelf registration statement.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating gross proceeds of approximately $500.0 million for the company. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders, with Nuvalent receiving no proceeds from this portion of the sale. J.P. Morgan, Jefferies, TD Cowen, and Cantor acted as joint book-running managers for the offering.
Nuvalent: Deerfield funds sell $70.8m in NUVL stock
Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P., tied to Nuvalent, Inc., sold 742,574 shares of Class A Common Stock for $70.8 million to cover over-allotments in a public offering. Despite the sale, Nuvalent's stock is near its 52-week high, and analysts maintain a "Strong Buy" consensus, although InvestingPro identifies the company as overvalued. Nuvalent recently completed a $500 million public offering and had its New Drug Application for zidesamtinib accepted by the FDA.
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nuvalent, Inc. announced that CEO James Porter and CFO Alexandra Balcom will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. ET. A live webcast and archived recording will be available on the company's website. Nuvalent is a clinical-stage biopharmaceutical company developing targeted therapies for cancer.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. Additionally, the underwriters fully exercised their option to purchase an extra 742,574 shares from selling stockholders, with Nuvalent receiving no proceeds from this secondary sale. The offering was managed by J.P. Morgan, Jefferies, TD Cowen, and Cantor.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders, with the sale closing on November 24, 2025. Nuvalent did not receive any proceeds from the sale of these additional shares.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. The underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders, with Nuvalent not receiving any proceeds from this sale. The offering supports Nuvalent's mission as a clinical-stage biopharmaceutical company focused on targeted cancer therapies.
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal
Nuvalent Inc. (NASDAQ: NUVL) successfully closed a public offering, selling 4,950,496 shares of Class A common stock at $101.00 per share, resulting in gross proceeds of approximately $500.0 million for the company. Additionally, underwriters fully exercised their option to purchase an extra 742,574 shares from selling stockholders, although Nuvalent did not receive any proceeds from this secondary sale. The offering strengthens Nuvalent's cash position for clinical programs and corporate purposes, but also results in share dilution for existing holders.
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders
Nuvalent, Inc. announced the closing of its underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, generating approximately $500.0 million in gross proceeds. Additionally, the underwriters fully exercised their option to purchase an additional 742,574 shares from selling stockholders, with Nuvalent not receiving any proceeds from this secondary sale. J.P. Morgan, Jefferies, TD Cowen, and Cantor acted as joint book-running managers for the offering.
Nuvalent Announces $500M Stock Offering Pricing
Nuvalent (NUVL) announced the pricing of an underwritten public offering of its Class A common stock at $101.00 per share, aiming to raise approximately $500 million. The offering is expected to close on November 20, 2025, and will fund the company’s operations and capital expenditures into 2029. An analyst recently rated NUVL stock as a Buy with a $158.00 price target, while TipRanks’ AI Analyst, Spark, rates it Neutral due to its high-risk, high-reward nature as an early-stage biotech firm.
Nuvalent prices $500 million public offering at $101 per share By Investing.com
Nuvalent, Inc. has priced an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, aiming to raise approximately $500 million. This move comes as the clinical-stage biopharmaceutical company trades near its 52-week high, with significant growth over the past six months and analysts suggesting continued losses for the current fiscal year. The capital will support its pipeline of targeted cancer therapies, including candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer.
Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, aiming to raise approximately $500.0 million in gross proceeds. The offering is expected to close on November 20, 2025, and includes an option for underwriters to purchase additional shares from selling stockholders, from which Nuvalent will not receive proceeds. J.P. Morgan, Jefferies, TD Cowen, and Cantor are serving as joint book-running managers for the transaction.
Nuvalent Announces Pricing of Public Offering of Common Stock
Nuvalent, Inc. announced the pricing of an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, expected to generate approximately $500.0 million in gross proceeds. The offering is anticipated to close on November 20, 2025. Additionally, selling stockholders have granted underwriters an option to purchase up to an additional 742,574 shares, from which Nuvalent will not receive proceeds.
Nuvalent prices $500 million public offering at $101 per share
Nuvalent Inc. has priced an underwritten public offering of 4,950,496 shares of Class A common stock at $101.00 per share, aiming to raise approximately $500 million in gross proceeds. This strategic capital raise occurs while the company's stock shows strong momentum, trading near its 52-week high with 42% growth over six months. The offering and recent positive results from its cancer drug trials reflect ongoing investor interest.
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering
Sidley represented Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company, in its US$500 million underwritten public offering. The offering involved 4,950,496 shares of Class A common stock at US$101.00 per share, with joint book-running managers including J.P. Morgan and Jefferies. The Sidley team, led by Rosemary Reilly and Craig Hilts, advised on the pricing and closing of the offering.
Why Did Nuvalent Stock Surge 15% Today?
Nuvalent (NUVL) shares surged over 15% following strong topline results from its ALKOVE-1 Phase 1/2 trial for Neladalkib, an investigational drug for advanced ALK-positive non-small cell lung cancer. The trial showed high objective response rates, especially in lorlatinib-naïve patients, and demonstrated activity in brain tumors with a manageable safety profile. Analysts from Stifel and Leerink raised their price targets and reiterated positive ratings based on the compelling data.
Nuvalent Announces Public Offering of Common Stock
Nuvalent, Inc. (Nasdaq: NUVL) announced an underwritten public offering of $500.0 million of Class A common stock. The offering is subject to market conditions, and two Deerfield funds also plan to grant underwriters an option to purchase additional shares. Nuvalent will not receive proceeds from the sale of shares by the Selling Stockholders.
Nuvalent Announces Public Offering of Common Stock
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced the commencement of an underwritten public offering of $500.0 million of Class A common stock. The offering is subject to market and other conditions, with J.P. Morgan, Jefferies, TD Cowen, and Cantor acting as joint book-running managers. Nuvalent will not receive proceeds from any shares sold by the Selling Stockholders, who also have an option to sell additional shares.
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
Nuvalent, Inc. announced that it will host a webcast and conference call on November 17, 2025, to discuss topline pivotal data for neladalkib. This investigational ALK-selective inhibitor is being evaluated in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial. Neladalkib has received FDA breakthrough therapy and orphan drug designations for ALK-positive NSCLC.
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
Nuvalent presented preliminary data for neladalkib in advanced ALK-positive solid tumors beyond NSCLC at the ESMO 2025 conference. This presentation highlights the ongoing development and potential therapeutic applications of neladalkib in a broader range of cancers. The data will be of interest to researchers and clinicians focusing on ALK-positive malignancies.
Nuvalent Announces Upsized $575M Public Offering of Common Stock
Nuvalent, Inc., a clinical-stage biopharmaceutical company, announced an upsized $575 million public offering of common stock. The legal team from WilmerHale, including Rosemary G. Reilly, Jeffries Oliver-Li, Wiliam Hall, and Ashton Kennedy, represented Nuvalent in this transaction.
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 - The Malaysian Reserve
Nuvalent will present preliminary data for neladalkib in advanced ALK-positive solid tumors beyond non-small cell lung cancer (NSCLC) at the ESMO 2025 conference. This presentation will highlight new findings on the therapeutic potential of neladalkib for a broader range of ALK-driven cancers. The data is expected to provide insights into its efficacy and safety profile in these specific tumor types.
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 - Stock Titan
Nuvalent (NASDAQ: NUVL) reported encouraging preliminary ALKOVE-1 data for neladalkib in advanced ALK-positive solid tumors beyond NSCLC, presented at ESMO 2025. The study showed an overall objective response rate of 44% across 14 tumor types, with favorable safety and durability signals. Global Phase 2 enrollment is ongoing, and topline pivotal NSCLC data are anticipated by the end of 2025.
